Tetraphase Pharmaceuticals
Apr 29, 2013

Tetraphase Presents Data at ECCMID Supporting Efficacy of Two Antibiotic Candidates Against Multi-Drug Resistant Infections

- Oral Presentation and Poster Show Ability of Lead Candidate, Eravacycline, to Help Protect Against Community-Acquired, Complicated Intra-Abdominal Infections -

- Poster Shows Usefulness of Preclinical Candidate, TP-271, Against Community-Acquired Bacterial Pneumonia -

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it has presented results from studies that demonstrate efficacy of two next-generation antibiotic candidates against community-acquired multi-drug resistant (MDR) infections. These studies — which support the efficacy of the company's lead candidate, eravacycline, in the treatment of patients with community-acquired, complicated intra-abdominal infections (cIAIs), as well as the potential of pre-clinical candidate TP-271's activity against community-acquired bacterial pneumonia (CABP) — were described in one oral presentation and two poster presentations at the 23rd European Congress of Clinical Microbiology and Infectious Disease (ECCMID). The Congress occurs from April 27 to 30, 2013 in Berlin, Germany.

"These data continue to demonstrate the potential of our antibiotic franchise, both in terms of our lead candidate eravacycline, and the strength of our pre-clinical program, " said Guy Macdonald, Tetraphase President and Chief Executive Officer. "Antibiotic resistance, particularly among the difficult-to-treat populations with Gram-negative infections, represents a potential global health crisis. We are pleased by the results that our compounds display, particularly in the crucial areas of multi-drug resistant, community-acquired infections."

The oral presentation, which focused on results from a global Phase 2 trial, examined eravacycline compared to standard-of-care ertapenem for the treatment of community-acquired cIAIs. Results showed that eravacycline demonstrated efficacy in all populations at all study time points when examining both the microbiological activity of the pathogens and the clinical cure rates. The findings strongly support the use of eravacycline in the treatment of cIAI, including those hard-to-treat patients with multi-drug resistant gram-negative infections.

Following are details for each of Tetraphase's three presentations:

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections.

Investor Contacts:
Tetraphase Pharmaceuticals
David Lubner
Senior Vice President & CFO
Argot Partners
Susan Kim
Media Contact:
Sam Brown Inc.
Mike Beyer

Source: Tetraphase Pharmaceuticals, Inc.

News Provided by Acquire Media